Tencent has backed antimicrobial therapy developer Locus Biosciences in a $19m round that will fund the company's first in-human clinical trial.
US-based antimicrobial therapy developer Locus Biosciences completed a $19m series A round on Tuesday that included internet group Tencent.
Artis Ventures led the round, with contributions from fellow venture capital firm Abstract Ventures, non-profit research organisation North Carolina Biotechnology Centre and undisclosed others.
Founded in 2015, Locus has been using Crispr genome editing technology to develop therapies that treat antibiotic-resistant superbugs by targeting the bacterial DNA. The funding will be used to support the company through its first in-human clinical…
